February 27 – March 2, 2026, Philadelphia, PA, USA

American Academy of Allergy Asthma & Immunology (AAAAI)

Oral icon

Remibrutinib decreases urticaria disease activity leading to improved disease control: An analysis from the REMIX‑1/‑2 studies

Sarbjit Saini, Vipul Jain, Eric Boren, Huiping Wang, Hidetoshi Takahashi, Nadine Chapman-Rothe, Sibylle Haemmerle, George Vamvakas, Martin Metz
Abstract Poster
Oral icon

Remibrutinib provides fast symptom relief within the first week of treatment in chronic spontaneous urticaria, as measured by daily Urticaria Activity Score: Pooled REMIX-1/-2 studies

Hugh Windom, Paula Machado, Christine-Elke Ortmann, Nadine Chapman-Rothe, Tao Ding, Mark Lebwohl, Ansgar Weyergraf, Hui Tang, Michihiro Hide, John Reed
Abstract Poster
Oral icon

A novel panel of autoantibodies may assist in the molecular diagnosis of CSU

Sarbjit Saini, Martin Metz, Michihiro Hide, Theodoulos Rodosthenous, Alexandre Avrameas, Christoph Kollenda-Strunk, Ann-Sophie Lindemann, Annika Loredana Kilian, Petra Budde, Manuel Bräutigam, Hans-Dieter Zucht, Bruno Cenni, Ulf Gehrmann, Nadine Chapman-Rothe, Sibylle Haemmerle
Abstract Poster
Oral icon

Patients with CSU in the US: Health Care Resource Utilization by level of disease control

Marc A. Riedl, Dhaval Patil, Jonathan Rodrigues, Merin Kuruvilla, Jason Doran, Irina Pivneva, Frédéric Kinkead, Panagiotis Orfanos, Tara Raftery, Gil Yosipovitch
Abstract Poster
Novartis logo
FA-11248855-1     08/26
Cookie Settings
© Copyright 2026 Novartis Pharma AG